Yahoo Finance

4DMT Announces Presentation on Aerosolized 4D-710 for Treatment of Cystic Fibrosis at the American Society of Gene & Cell Therapy (ASGCT) 26th Annual Meeting

EMERYVILLE, Calif., May 11, 2023 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT), a clinical-stage biotherapeutics company harnessing the power of directed evolution for targeted genetic ...
Nasdaq

4D Molecular Therapeutics Announces Presentations at ASRS 2025 on Phase 2 Clinical Trials for 4D-150 in Diabetic Macular Edema and Neovascular Age-related Macular Degeneration

4D Molecular Therapeutics is actively presenting interim and 52-week results from their clinical trials at a prominent scientific conference, highlighting their commitment to advancing innovative ...
Yahoo Finance

4D Molecular Therapeutics Announces Late-Breaking Presentation of 4D-125 Clinical Data at the Upcoming ASRS Annual Meeting

4DMT is currently enrolling patients in an on-going Phase 1/2 dose-escalation and dose-expansion clinical trial assessing intravitreal 4D-125, 4DMT’s targeted and evolved R100-based product candidate ...
The Globe and Mail

4D Molecular Therapeutics Announces Preclinical Data Presentations at ASGCT and ATS Annual Meetings on Three Wholly-Owned Product Candidates from Non-Human Primate Studies

- Abstracts on 4D-150 for wet AMD/DME and 4D-310 for Fabry disease accepted for oral presentations at ASGCT 24 th Annual Meeting - Abstract on 4D-710 for cystic fibrosis lung disease accepted for oral ...